Turn Therapeutics (NASDAQ:TTRX) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a research report report published on Sunday morning,Wall Street Zen reports.

A number of other equities analysts have also issued reports on the company. Zacks Research raised Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings downgraded Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Finally, LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Turn Therapeutics Price Performance

TTRX stock opened at $12.69 on Friday. The company has a fifty day moving average price of $9.71 and a 200 day moving average price of $6.28. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $26.50. The company has a market cap of $378.04 million and a price-to-earnings ratio of -43.76. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. Sell-side analysts expect that Turn Therapeutics will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TTRX. HighTower Advisors LLC acquired a new stake in Turn Therapeutics in the fourth quarter valued at about $78,000. Wellington Shields & Co. LLC acquired a new position in Turn Therapeutics during the 4th quarter worth approximately $259,000. Geode Capital Management LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $68,000. LPL Financial LLC purchased a new position in shares of Turn Therapeutics during the 4th quarter worth approximately $51,000. Finally, Hodges Capital Management Inc. acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $39,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.